Current guidelines recommend off-label use of cyclosporine and systemic glucocorticoids as the primary systemic treatment for pregnant women with atopic dermatitis (AD). Longitudinal claims data of commercially insured women was used to investigate the usage of systemic and topical medications for AD during pregnancy following the approval of dupilumab.
Read more at the Journal of the American Academy of Dermatology.